Pomerantz Law Firm Investigates Alnylam Pharmaceuticals Following Significant Stock Price Decline

Pomerantz LLP has launched an investigation into Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) to determine if the company or its executives engaged in securities fraud or unlawful business practices. The probe follows a sharp decline in the company's stock price after its third-quarter financial results were released on October 29, 2026. The investigation is centered on reports of slowing demand for Amvuttra, a transthyretin-mediated amyloidosis treatment that constitutes 87.5% of Alnylam's total product sales. Specifically, U.S. total transthyretin demand growth was reported at $81 million, a significant decrease from the $129 million recorded in the previous quarter. The market reacted sharply to these findings, with Alnylam's stock price plummeting 25.13% to close at $174.00 on the day of the announcement.

By Pomerantz LLP · PR Newswire ·

Pomerantz Law Firm Investigates Alnylam Pharmaceuticals Following Significant Stock Price Decline

Tickers: $ALNY

Topics: class action lawsuit earnings report impact securities fraud investigation stock price volatility

Read the full article at PR Newswire

More World news